• Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Pinterest Social Icon
  • Instagram Social Icon

September 2, 2018

Please reload

Recent Posts

I'm busy working on my blog posts. Watch this space!

Please reload

Featured Posts

Dronabinol not effective for opioid withdrawal

November 11, 2017

 

https://www.facebook.com/novaddiction/ Facebook page Novaddiction Addiction Treatment center

 

Suboxone treatment center in Northern Virginia - Telemedicine available <<Click here

Suboxone treatment Fairfax, woodbridge, Front Royal using telemedicine   < 703-844-0184

 

Endocannabinoid system as potential target for opioid withdrawal treatment

 

 

Lofwall, M.R., et al. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.

 

 

 

 

 

 

 

 

 

 

 

The bottom line of the research was to show if Dronabinol (used as an appetite stimulant) could suppress opioid withdrawal symptoms - it was unfortunately not effective as expected:

:CB1 receptor activation is a reasonable strategy to pursue for the treatment of opioid withdrawal; however, dronabinol is not a likely candidate given its modest withdrawal suppression effects
of limited duration and previously reported tachycardia during opioid withdrawal.

 

Dronabinol, a partial CB1 agonist, was evaluated among adults in opioid withdrawal.

Dronabinol 20 and 30 mg doses produced modest evidence of withdrawal suppression.

Higher acute oral doses also produced sinus tachycardia.

Dronabinol is not a likely mono-therapy candidate for opioid withdrawal treatment.

 

Article brief pasted: 

Finding new medications to effectively alleviate opioid withdrawal is an important step in enabling transition to medication protocols to treat opioid use disorders. Many patients drop out of treatment early if they cannot tolerate the withdrawal period and are then unable to start medications.

The endocannabinoid system is a potential novel target for opioid withdrawal treatment. Scientists supported by the National Institute on Drug Abuse conducted a proof-of-concept study examining the potential efficacy of a cannabinoid receptor (CB1) partial agonist, dronabinol, in relieving signs and symptoms of opioid withdrawal. (An agonist means it activates the cannabinoid receptors). Dronabinol is a synthetic form of cannabis approved by the Food and Drug Administration to treat loss of appetite that causes weight loss in people with AIDS.

Twelve opioid dependent adults participated in this five-week, inpatient, double-blind, randomized, placebo-controlled study. Results suggest that lower doses of dronabinol (i.e., 5 and 10 mg) produced effects similar to placebo, while higher doses (i.e., 20 and 30 mg) modestly suppressed withdrawal, but also produced sedation and impairment, a feeling of being high, and unpleasant sensations like a racing heart.

The authors conclude that while CB1 receptor activation is a reasonable strategy to pursue for the treatment of opioid withdrawal, it is not a likely candidate given its modest withdrawal suppression effects and concerning effects on heart rate. Instead, they suggest exploring other CB1 agents or medications with different mechanisms of action on the endocannabinoid system to treat opioid withdrawal.

However, CB1 receptor activation may be a reasonable strategy to pursue.

 

https://www.suboxonefairfax.com - Suboxone treatment drug addiction treatment in Fairfax and Alexandria, Virginia

https://www.suboxonefairfax.com - Suboxone treatment drug addiction treatment in Fairfax and Alexandria, Virginia

 

Share on Facebook
Share on Twitter
Please reload

Follow Us
Search By Tags